The combination of toll-like receptor 4 and 7 agonists suppresses colon carcinoma via tumor microenvironment modulation and potential granzyme-mediated cytotoxicity
Year: 2026
Type: article
Abstract: Background Overcoming the immunosuppressive tumor microenvironment (TME) is a major challenge in cancer immunotherapy. Building on combined TLR agonist studies, we introduce compound 2 as a novel TLR7 agonist and test it alone and with a TLR4 agonist for TME reprogramming and antitumor immunity in colon carcinoma. Methods The activity of compound 2 and its combined effects with TLR4 agonist were first evaluated in vitro by assessing NF-κB signaling activation, dendritic cell maturation and proinflammatory cytokine production. In vivo , compound 2 and a TLR4 agonist were intratumorally co-delivered to CT26 tumor-bearing mice. Tumor growth and survival were monitored. The intratumoral immune landscape was profiled via flow cytometry, and transcriptomic analysis was performed to elucidate underlying mechanisms. Systemic toxicity was assessed by hematological and organ toxicity tests. Results Compound 2 exhibited TLR7 agonist activity, and its combination with a TLR4 agonist markedly enhanced NF-κB signaling and, in vitro , induced maturation of bone-marrow-derived dendritic cells, leading to elevated proinflammatory cytokines. In mouse models, this combination significantly suppressed tumor growth and prolonged survival. Immune profiling revealed treatment-associated shifts in the relative frequencies of intratumoral immune populations, including higher frequencies of cytotoxic T cells, natural killer cells, and M1 macrophages, and lower frequencies of monocytic cells, M2 macrophages, CD11b + Siglec-H + cells and CD11b + CD11c + MHC-II + cells, and CD8 + PD-1 + T cells. Because these values are relative frequencies of live cells, they do not establish changes in absolute abundance. Transcriptomic analysis revealed enrichment of granzyme-mediated apoptotic pathways, consistent with known cytotoxic lymphocyte effector mechanisms, and gene signatures associated with reduced tumor burden. Conclusion Co-activation of TLR7 by compound 2 and TLR4 represents a promising strategy to shift the intratumoral immune balance toward cytotoxic effector frequencies, and extends earlier combined TLR agonist approaches. This approach is associated with shifts in the tumor microenvironment and with enhanced cytotoxic immunity, suppresses tumor growth, and was well tolerated at the doses tested, highlighting its potential for enhancing immunotherapy in accessible tumors such as colon carcinoma.
Source: Frontiers in Immunology
Authors: Changcai Teng(Data curation, Investigation, Methodology, Project administration, Writing – original draft), Juan Hou(Methodology, Writing – original draft), Xiongyan Meng(Methodology, Writing – original draft), Xin Wang(Investigation, Methodology, Writing – review & editing), Yong Rao(Investigation, Methodology, Writing – review & editing), Qi Gao(Resources, Validation, Writing – review & editing), Chengli Zong(Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Resources, Supervision, Writing – review & editing)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236816363
